Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

Lambertini, Matteo; Ceppi, Marcello; Cognetti, Francesco; Cavazzini, Giovanna; Laurentiis, Michelino De; Placido, Sabino De; Michelotti, Andrea; Bisagni, Giancarlo; Durando, Antonio; Valle, Elisabetta Della; Scotto, Tiziana; Censi, Andrea De; Turletti, Anna; Benasso, Marco; Barni, Sandro; Montemurro, Filippo; Puglisi, Fabio; Levaggi, Alessia; Giraudi, S.; Bighin, Claudia; Bruzzi, Paolo; Mastro, Lucia Del; groups, Gim study

doi:10.1016/j.ejca.2016.10.030

Cited by 40 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The unplanned subgroup analysis provided some evidence of an interaction between age and treatment, with a numerical OS benefit for younger patients (<50 years) when treated with ddAC compared with TAC and for older patients (!50 years) when treated with TAC compared with ddAC. These results are in line with a previous report on improved survival after dosedense chemotherapy compared with standard-interval chemotherapy in young breast cancer patients [20]. Also, higher survival rates are observed in older patients treated with taxane-containing regimens compared with patients of the same age treated with non-taxaneebased regimens [1,21].…”

Section: Discussionsupporting

confidence: 91%

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Rossum

Kok

Werkhoven

et al. 2018

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Rossum

Kok

Werkhoven

et al. 2018

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…We did capture BRCA status in most patients, but we did not calculate their Gail Model Risk Score or include information about other cancer‐predisposition genes. Different chemotherapy regimens, including the combination of chemotherapeutics and whether or not the course is dose‐dense, may have differing effects . We also did not collect data to assess whether the patients in the neoadjuvant chemotherapy group had a complete or incomplete pathologic clinical response to their chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Fertility preservation before breast cancer treatment appears unlikely to affect disease‐free survival at a median follow‐up of 43 months after fertility‐preservation consultation

Letourneau

Wald

Sinha

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to determine whether fertility preservation (FP) with oocyte/embryo cryopreservation is associated with differences in disease-free survival (DFS). METHODS: This retrospective study included patients aged 18 to 45 who were diagnosed with invasive breast cancer between 2007 and 2017 and were seen for FP consultation at a university fertility center before cancer treatment. The primary endpoint, DFS, was defined as the time from FP consultation until patients developed a locoregional recurrence, distant metastasis, a contralateral breast tumor, or a new primary malignancy. DFS was compared for FP versus no FP using Kaplan-Meier survival estimates and Cox proportional-hazard regression analysis. RESULTS: The study included 329 women, with 207 (63%) in the FP group and 122 (37%) in the no FP group. Patients who underwent FP had more aggressive initial disease profiles than those in the no FP group. In addition, they were younger (35 vs 37 years; P = .009), more often had stage II or III disease (67% vs 55%; P = .03), and had higher rates of requiring chemotherapy (77% vs 65%; P = .01). Over a median follow-up of 43 months, the rates of DFS were similar among patients in the FP group and the no FP group (93% vs 94%, respectively; hazard ratio [HR] 0.7; 95% CI, 0.3-1.7). Positive ER status (79% vs 83%; P = .38), neoadjuvant chemotherapy (41% vs 48%; P = .32), ER-positive DFS (HR, 0.4; 95% CI, 0.1-1.6), and neoadjuvant chemotherapy DFS (HR, 1.4; 95% CI, 0.2-9.1) were similar in the FP and no FP groups, respectively. CONCLUSIONS: At a median follow-up of 43 months, FP appears unlikely to affect DFS, even in the setting of tumors with positive ER status or treatment with neoadjuvant chemotherapy (in which the tumor remains in situ during FP). Cancer 2020;126:487-495.

show abstract

“…For this reason, it is not feasible to use GnRH analogs in female patients scheduled to receive pelvic, abdominal, or TBI. According to ASCO, ASRM, and ESMO guidelines [23][24][25][26][27][28][29], GnRH analogs and other hormonal suppression methods with oral contraceptives should not be relied upon as female fertility preservation methods; however, the most recent publications encourage the use of GnRH analogs to preserve female fertility during chemotherapy, particularly for patients with breast cancer [106][107][108][109][110][111][112][113][114][115][116][117]. In women of reproductive age with hematological malignancies, we consider GnRH analogs still debatable as few reports showed controversial results of GnRH analogs treatment for the prevention of anticancer therapy-induced POI and fertility loss [113,[118][119][120][121][122][123].…”

Section: Fertility Preservation and Restoration Options In Female Patmentioning

confidence: 99%

Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach

2019

View full text Add to dashboard Cite

Oncofertility is a new interdisciplinary field at the intersection of oncology and reproductive medicine that expands fertility options for young cancer patients. The most common forms of hematological malignancies that occur in girls and young women and therefore necessitate oncofertility care are acute lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. Aggressive gonadotoxic anticancer regimens including alkylating chemotherapy and total body irradiation are used often in treating girls and young women with hematological malignancies. The risks of gonadotoxicity and subsequent iatrogenic premature ovarian insufficiency and fertility loss depend mainly on the type and stage of the disease, dose of anticancer therapy as well as the age of the patient at the beginning of treatment. To avoid or at least mitigate the devastating complications of anticancer therapy-induced gonadotoxicity, effective and comprehensive strategies that integrate different options for preserving and restoring fertility ranging from established to experimental strategies should be offered before, during, and after chemotherapy or radiotherapy. A multidisciplinary approach that involves strong coordination and collaboration between hemato-oncologists, gynecologists, reproductive biologists, research scientists, and patient navigators is essential to guarantee high standard of care.

show abstract

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

Cited by 40 publications

References 26 publications

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Fertility preservation before breast cancer treatment appears unlikely to affect disease‐free survival at a median follow‐up of 43 months after fertility‐preservation consultation

Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach

Contact Info

Product

Resources

About